Elicio Therapeutics, Inc.
corporate_fare Company Profile
Elicio Therapeutics, Inc. (NASDAQ:ELTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ELTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 15 rated 8 or above. Recent SEC coverage for ELTX spans 10-Q, 8-K, 10-K/A, 424B5.
Recent high-impact activity:
- Elicio 10-Q: Q3 Loss Narrows to $8.0M, Going Concern Reiterated, Cash to Q2 2027
- Elicio Q3 Loss Narrows to $8.0M; Cash Runway Extended to Q2 2027
- Elicio's Lead Cancer Vaccine Misses Primary Endpoint in Phase 2 Trial
- Q2 2026 results show a narrower net loss and extended cash runway into Q1 2027
- Elicio Therapeutics Closes $15M Registered Direct Offering, Funds Clinical Development
Financial Snapshot
Short Interest & Short Volume
5.87 days to coverFINRA reported short interest of 1,836,661 shares in ELTX as of the October 30, 2026 settlement, a 7.9% increase from the prior period — about 5.9 days to cover at its recent average daily volume. On November 20, 2026, 38.1% of ELTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Recent Capital Actions
-
2026-02-27 Proposed Shelf Only $400M